These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32034693)

  • 41. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study.
    Naik H; Stoecker M; Sanderson SC; Balwani M; Desnick RJ
    Mol Genet Metab; 2016 Nov; 119(3):278-283. PubMed ID: 27595545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria.
    Melch M; Lee J; Jomphe C; Robbie GJ
    Clin Pharmacokinet; 2023 Jan; 62(1):89-99. PubMed ID: 36633811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Remission of Delta-Aminolevulinic Acid Dehydratase Deficiency Through Suppression of Erythroid Heme Synthesis.
    Neeleman RA; van Beers EJ; Friesema EC; Koole-Lesuis R; van der Pol WL; Wilson JHP; Langendonk JG
    Hepatology; 2019 Jul; 70(1):434-436. PubMed ID: 30724374
    [No Abstract]   [Full Text] [Related]  

  • 44. Neurology of the acute hepatic porphyrias.
    Oliveira Santos M; Leal Rato M
    J Neurol Sci; 2021 Sep; 428():117605. PubMed ID: 34375916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Production of 5-aminolevulinic acid by an Escherichia coli aminolevulinate dehydratase mutant that overproduces Rhodobacter sphaeroides aminolevulinate synthase.
    Xie L; Eiteman MA; Altman E
    Biotechnol Lett; 2003 Oct; 25(20):1751-5. PubMed ID: 14626421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of the enzymic errors in the various porphyrias.
    Rimington C
    Scand J Clin Lab Invest; 1985 Jun; 45(4):291-301. PubMed ID: 3892647
    [No Abstract]   [Full Text] [Related]  

  • 47. [delta-Aminolevulinate dehydratase deficiency].
    Fujita H; Ishida N; Akagi R
    Nihon Rinsho; 1995 Jun; 53(6):1408-17. PubMed ID: 7616655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria].
    Stölzel U
    Z Gastroenterol; 2020 Aug; 58(8):785. PubMed ID: 32785915
    [No Abstract]   [Full Text] [Related]  

  • 49. Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts.
    Wheeden K; Lyon Howe D; Burrell S; Gill L; Chamberlayne J; Williams ER; Simon A; Ko JJ; Mora J; Wells T; Evans C; Paulich M; Meninger S; Lombardelli S
    Adv Ther; 2022 Sep; 39(9):4330-4345. PubMed ID: 35907153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute hepatic porphyria and cancer risk: a nationwide cohort study.
    Baravelli CM; Sandberg S; Aarsand AK; Nilsen RM; Tollånes MC
    J Intern Med; 2017 Sep; 282(3):229-240. PubMed ID: 28730628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detecting rare diseases in electronic health records using machine learning and knowledge engineering: Case study of acute hepatic porphyria.
    Cohen AM; Chamberlin S; Deloughery T; Nguyen M; Bedrick S; Meninger S; Ko JJ; Amin JJ; Wei AJ; Hersh W
    PLoS One; 2020; 15(7):e0235574. PubMed ID: 32614911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The clinical importance of early acute hepatic porphyria diagnosis: a national cohort.
    Edel Y; Mamet R; Cohen S; Shepshelovich D; Levi A; Sagy I
    Intern Emerg Med; 2021 Jan; 16(1):133-139. PubMed ID: 32372331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case report of a complicated neurologically manifesting acute porphyria treated successfully with Givosiran.
    Steinberg T; Kilic M; Fuchs K; Hanyk K; Linker RA; Schlachetzki F; Neumann B
    J Neurol Sci; 2021 Mar; 422():117334. PubMed ID: 33581419
    [No Abstract]   [Full Text] [Related]  

  • 54. Regulation of heme metabolism in rat hepatocytes and hepatocyte cell lines: delta-aminolevulinic acid synthase and heme oxygenase are regulated by different heme-dependent mechanisms.
    Cable EE; Miller TG; Isom HC
    Arch Biochem Biophys; 2000 Dec; 384(2):280-95. PubMed ID: 11368315
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic siRNA: state of the art.
    Hu B; Zhong L; Weng Y; Peng L; Huang Y; Zhao Y; Liang XJ
    Signal Transduct Target Ther; 2020 Jun; 5(1):101. PubMed ID: 32561705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute Hepatic Porphyrias: "Purple Flags"-Clinical Features That Should Prompt Specific Diagnostic Testing.
    Anderson KE; Desnick RJ; Stewart MF; Ventura P; Bonkovsky HL
    Am J Med Sci; 2022 Jan; 363(1):1-10. PubMed ID: 34606756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ALAS1 gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FOXO1 by vanadate in diabetic mice.
    Oliveri LM; Davio C; Batlle AM; Gerez EN
    Biochem J; 2012 Mar; 442(2):303-10. PubMed ID: 22070747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular aspects of the inherited porphyrias.
    Sassa S; Kappas A
    J Intern Med; 2000 Feb; 247(2):169-78. PubMed ID: 10692079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias.
    Barman-Aksözen J; Suter L; Wegmann F; Meienberg J; Minder AE; Beer M; Komminoth P; Minder EI; Schneider-Yin X
    Scand J Clin Lab Invest; 2019 Sep; 79(5):305-313. PubMed ID: 31154864
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enzyme aspects of acute intermittent porphyria.
    Tschudy DP
    Mol Cell Biochem; 1973 Nov; 2(1):63-70. PubMed ID: 4358000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.